AstraZeneca, Ironwood deal

AstraZeneca granted Ironwood exclusive, U.S. rights to Zurampic lesinurad, which FDA approved in December in combination with a xanthine oxidase inhibitor

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE